checkAd

     109  0 Kommentare Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers - Seite 3

    Lesen Sie auch


    at the time of publication of the news with a raise of +6,80 % to 1,397 on Tradegate stock exchange (22. August 2023, 22:26 Uhr).

    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers - Seite 3 Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program …